Our mission is to harness the great promise offered by stem cell technology towards the treatment, and possibly cure, of a broad array of intractable human disease for the benefit of patients, family members, physicians and society in general.
|
|
|
StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and enabling technologies for use in stem cell-based research and drug discovery. Our cellular medicine programs target diseases of the central nervous system (CNS) and Liver.
We are a world leader in the discovery and development of human neural stem cell technology.
Our lead product candidate, HuCNS-SCŪ cells (purified human neural stem cells), is in clinical development for the treatment
of two fatal neurodegenerative disorders that primarily affect young children.
|
StemCells also markets specialty cell culture products under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery, and development.
Our strong intellectual property position includes exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents.
Our scientific founders, who are also members of our Scientific Advisory Board, are recognized as world leaders in stem cell biology.
|
Stem Cell Sciences Acquisition
In April 2009, we acquired the operations of Stem Cell Sciences plc. This acquisition solidifies our leadership position in human neural stem cell technology, broadens our proprietary cell-based technologies, adds expertise and infrastructure for providing cell-based assays for drug discovery and screening, adds a revenue-generating cell culture media business, and establishes a European presence with operations in Cambridge, U.K.
Read more about the acquisition.
|
PHASE I CLINICAL TRIAL IN PMD
|
|
|
|
|
